Actualités

FDA approves an extended once-every-eight-weeks maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis. The decision expands Eli Lilly's (NYSE:LLY) dermatology footprint beyond its obesity and diabetes drug franchises. Ebglyss already has broad coverage from national pharmacy benefit managers, and the new regimen provides added dosing flexibility for patients. For you as an investor, this FDA decision adds another dimension to Eli Lilly's...

I keep buying NVIDIA, Eli Lilly, and Johnson & Johnson, and if a fire took my brokerage statement to zero tomorrow, those are the three tickers I would start typing in again on day one. They each do something I cannot replicate by being clever. Why the buy button stays active on NVIDIA NVIDIA (NASDAQ:NVDA) ... I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

LLY wins FDA approval for every-8-week Ebglyss maintenance dosing in eczema, reducing injections per year while maintaining long-term disease control.

Eli Lilly and other defensive names gain favor as AI overspending fears spark a sharp rotation out of tech and semiconductor stocks.

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

If ACD680 were to reach the market, it would deepen Lilly’s Alzheimer’s legacy past anti-amyloid-beta therapy, Kisunla.

By Chris Prentice and Maggie Fick NEW YORK/LONDON, June 10 (Reuters) - Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible new entrants to

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.

Pfizer (NYSE:PFE) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight quarterly EPS beats before stumbling in Q1. Yet the stock is up only 6.37% YTD this year. Can Pfizer shares double to $50 by 2031? What’s Holding Pfizer Back Pfizer is down 0.23% over the past month and essentially flat ... Prediction: Pfizer Stock Will Double on This Date

Eli Lilly’s latest analyst update comes with no changes to the existing price targets, keeping the current benchmarks in place for now. In the sections ahead, you will see how to track these price targets over time and follow the evolving analyst narrative around the stock. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Eli Lilly. Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the...

Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Dividend Stocks to Buy According to D. E. Shaw. On June 9, Jefferies raised its price recommendation on Eli Lilly and Company (NYSE:LLY) to $1,350 from $1,330. It reiterated a Buy rating on the shares. The move followed the release of full data from […]

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy. On June 7, Eli Lilly’s oral GLP-1 medication, Foundayo (orforglipron), demonstrated significant efficacy in promoting weight loss for women across all stages of menopause. Results from post-hoc analyses of the ATTAIN-1 and ATTAIN-2 clinical trials, presented at the American Diabetes […]

FDA approval expands EBGLYSS maintenance dosing to once every eight weeks, offering fewer injections for patients with moderate-to-severe atopic dermatitis.

The milestone shows strong early demand as Novo competes with Lilly in oral weight-loss drugs.

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and

Dow Jones AI giant Nvidia stock tumbled to a key support level during Tuesday's stock market sell-off. A decisive bounce would be bullish.

AI Stocks are getting hammered on renewed overspending fears. Is this the start of the end?

Eli Lilly (NYSE:LLY) has entered a collaboration and licensing agreement with AlzeCure Pharma for global rights to Alzstatin ACD680, a preclinical Alzheimer's therapy. The deal structure includes potential payments that could exceed US$1b if development, regulatory and commercial milestones are reached. The agreement expands Lilly's neuroscience and Alzheimer's disease pipeline beyond its existing focus on obesity and metabolic treatments. Eli Lilly is best known today for its obesity and...

Eli Lilly (NYSE:LLY) is finally acting like a trillion-dollar drugmaker again. After a brutal stretch in late 2025 and a wobbly start to this year, the stock punched through fresh 52-week highs on retatrutide Phase 3 data that analysts call potentially first-line for obesity. The stock trades at $1,149.15 with a one-year gain of 50.31%, ... Prediction: Eli Lilly Will Trade at This Price in a Year

AlzeCure Deal Expands Lilly's Neuroscience Pipeline Early

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.

Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.

For most investors, the race to become the world’s most valuable company feels like a contest between Nvidia (NASDAQ:NVDA) and a handful of AI-first businesses. Yet a growing number of investors are starting to think the biggest AI winner may be a company emerging from industries already possessing something harder to build than a large ... Forget Nvidia and SpaceX. This 150-Year-Old Indiana Company Could Become the World’s Largest in 5 Years

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

OpenAI confidentially files IPO paperwork, Apple’s AI reveal, Wall Street likes Lilly over Novo in weight-loss wars, and more news to start your day.

Eli Lilly (LLY) shares were up early Tuesday as the drugmaker entered into a collaboration and licen

(Bloomberg) -- The Pentagon accused some of China’s biggest companies, including Alibaba Group Holding Ltd., Baidu Inc. and BYD Co. of supporting the Chinese military, doubling down on an earlier decision to label crown jewels of the country’s corporate world as threats to US national security.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’LA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump Says He, Not Congress, Is in Charge of Kennedy Center